Regenxbioの空売り状況は、投資家がRegenxbioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Regenxbio (NASDAQ:RGNX) 株価情報, 空売り情報

Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Inc

<p>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $0.73 by 57.53 percent. This is a 134.69 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $239.72 million which beat the analyst consensus estimate of $237.00 million by 1.14 percent. This is a 24.52 percent increase over sales of $192.51 million the same period last year.</p>


Earnings

News

INSP

Inspire Medical Systems Q4 EPS $1.15 Beats $0.73 Estimate, Sales $239.72M Beat $237.00M Estimate

<p>Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.19 by 21.05 percent. This is a 66.67 percent decrease over earnings of $0.45 per share from the same period last year.  The company reported quarterly sales of $117.419 million which beat the analyst consensus estimate of $117.091 million by 0.28 percent.  This is a 31.17 percent decrease over sales of $170.596 million the same period last year.</p>


Earnings Beats

Earnings Misses

LSCC

Lattice Semiconductor Q4 2024 Adj. EPS $0.15 Misses $0.19 Estimate, Sales $117.419M Beat $117.091M Estimate

Guidance

VRTX

Vertex Pharmaceuticals Sees FY25 Revenue $11.75B-$12.00B vs. $11.84B Est.

<p>Sera intends to use the net proceeds from the proposed offering to expand its commercial infrastructure and capabilities in the United States, accelerate preparations for expansion in the European Union, fund additional studies designed to increase adoption of the PreTRM test, including a potential submission to the U.S. Food and Drug Administration (the "FDA") seeking broad approval of the PreTRM test, and for general corporate purposes.&nbsp;<br />&nbsp;</p>


Offerings

SERA

Sera Prognostics Commences Proposed Public Offering Of Its Class A Common Stock And, In Lieu Of Class A Common Stock To Certain Investors, Pre-funded Warrants

Vertex Pharmaceuticals Q4 2024 Adj. EPS $3.98 Misses $4.03 Estimate

<ul>
<li>Revenues of €9.2 million for the full year of 2024</li>
<li>Cash and cash equivalents at €96.6 million as of December 31, 2024</li>
<li>First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 million</li>
<li>Last patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early January 2025 and randomization of the last patient expected within the first half of 2025</li>
<li>Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50%</li>
</ul>


Management

Inventiva Reports €9.2M 2024 Revenues, €96.6M Cash As Of December 31, 2024; €116M Tranche Of €348M Financing Secured; Last Patient Screened For NATiV3 Phase 3 Lanifibranor Trial; Workforce Cut By 50% To Focus On Lanifibranor Development

<p>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported quarterly earnings of $3.50 per share which missed the analyst consensus estimate of $3.57 by 1.96 percent.  The company reported quarterly sales of $2.912 billion which beat the analyst consensus estimate of $2.781 billion by 4.70 percent.  This is a 15.66 percent increase over sales of $2.518 billion the same period last year.</p>


Vertex Pharmaceuticals Q4 2024 GAAP EPS $3.50 Misses $3.57 Estimate, Sales $2.912B Beat $2.781B Estimate

Lattice Semiconductor Appoints Lorenzo Flores As CFO

<p>Ratings for SS&amp;C Techs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $98.57, along with a high estimate of $105.00 and a low estimate of $93.00. Witnessing a positive shift, the current average has risen by 13.48% from the previous average price target of $86.86.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739221265_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of SS&amp;C Techs Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SS&amp;C Techs Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of SS&amp;C Techs Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for SS&amp;C Techs Hldgs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SS&amp;C Techs Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SSNC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on SS&amp;C Techs Hldgs analyst ratings.</strong></a></p>
<h2>All You Need to Know About SS&amp;C Techs Hldgs</h2>
<p>SS&amp;C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&amp;C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&amp;C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&amp;C's purchase of Intralinks makes it a leading player in virtual data room solutions. With its 2018 purchase of DST Systems, SS&amp;C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&amp;C completed the acquisition of Blue Prism.</p>
<h3>SS&amp;C Techs Hldgs: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> SS&amp;C Techs Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>7.31%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> SS&amp;C Techs Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.22%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> SS&amp;C Techs Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.48%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.93%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> SS&amp;C Techs Hldgs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.08</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

SSNC

Forecasting The Future: 7 Analyst Projections For SS&C Techs Hldgs

<p>In the last three months, 8 analysts have published ratings on AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for AvalonBay Communities, revealing an average target of $238.75, a high estimate of $262.00, and a low estimate of $223.00. Marking an increase of 0.37%, the current average surpasses the previous average price target of $237.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739221257_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of AvalonBay Communities by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$229.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$230.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Adam Kramer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$223.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$242.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$243.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Paolone</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$262.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$241.00</td>
<td>$244.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AvalonBay Communities. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AvalonBay Communities compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for AvalonBay Communities's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AvalonBay Communities's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AVB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AvalonBay Communities analyst ratings.</strong></a></p>
<h2>Get to Know AvalonBay Communities Better</h2>
<p>AvalonBay Communities owns a portfolio of 286 apartment communities with over 86,000 units and is developing 19 additional properties with over 6,800 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington D.C., California, and the Pacific Northwest.</p>
<h3>AvalonBay Communities: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining AvalonBay Communities's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>5.26%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> AvalonBay Communities's net margin is impressive, surpassing industry averages. With a net margin of <strong>50.73%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AvalonBay Communities's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.15%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> AvalonBay Communities's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.76%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> AvalonBay Communities's debt-to-equity ratio is below the industry average at <strong>0.72</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 8 Analyst Ratings Have To Say About AvalonBay Communities

<p>Rep. <strong>Rosa DeLauro</strong> (D-CT) is calling out President <strong>Donald Trump</strong> and billionaire <strong>Elon Musk</strong>, accusing them of using international tensions as a smokescreen while working behind the scenes to slash funding for critical programs that support everyday Americans.</p>
<p>DeLauro last week took to <a href="https://x.com/rosadelauro/status/1887201984198926841">social media</a> to counter <a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">Trump's claim</a> that the U.S. is &#8220;taking over Gaza.&#8221; She dismissed the statement outright, saying, &#8220;No, we are not taking over Gaza. But President Trump saying that will be a perfect distraction from his and Elon Musk's true goal: billionaires robbing from the programs that help Americans get ahead.&#8221;</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">No, we are not taking over Gaza. But President Trump saying that will be a perfect distraction from his and Elon Musk's true goal: billionaires robbing from the programs that help Americans get ahead. <a href="https://t.co/KCwn4DOmX3">https://t.co/KCwn4DOmX3</a></p>
<p>&mdash; Rosa DeLauro (@rosadelauro) <a href="https://twitter.com/rosadelauro/status/1887201984198926841?ref_src=twsrc%5Etfw">February 5, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></strong></li>
<li><strong>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong> </strong><strong>you can become an investor for $0.80 per share today.</strong></a></strong></li>
</ul>
<p>DeLauro's concerns come as she <a href="https://democrats-appropriations.house.gov/news/press-releases/delauro-applauds-court-pausing-destruction-agency-central-us-national-security">applauded</a> a U.S. District Court decision blocking the Trump administration from placing more than 2,000 U.S. Agency for International Development workers on paid leave. She accused the administration of attempting to dismantle government agencies without congressional approval, calling it part of a broader Republican effort to cut vital funding for public services like Medicaid, public education, and health research.</p>
<p>"Elon Musk and his puppet President Trump" are unlawfully freezing resources families depend on, she claimed, while Republicans work behind closed doors to redirect taxpayer dollars toward the wealthy.</p>
<p>Although DeLauro offers a compelling argument, some contend that the Trump administration&#8217;s funding choices are a component of larger initiatives to cut back on government expenditures and promote private sector solutions. Supporters contend that scaling back certain federal programs could lead to more efficient resource allocation, fostering economic growth and reducing reliance on government aid.&nbsp;</p>
<p><strong>Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></p>
<h2 class="wp-block-heading">Funding Freeze Disrupts Public Health Services</h2>
<p>DeLauro has also <a href="https://democrats-appropriations.house.gov/news/press-releases/delauro-murray-baldwin-blast-trump-administration-halt-vital-work-nations">condemned</a> Trump's recent <a href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected">freeze on federal funding</a> at the Department of Health and Human Services, which has impacted Medicaid, Head Start, and public health initiatives.&nbsp;</p>
<p>While a White House memo ordering the freeze <a href="https://www.benzinga.com/news/25/01/43322173/trumps-memo-freezing-federal-assistance-money-rescinded-by-another-memo-following-lawsuits">was later rescinded</a>, lawmakers say the damage continues, with programs still facing uncertainty.</p>
<h2 class="wp-block-heading">Musk Accused of Blocking U.S.-China Investment Restrictions</h2>
<p>In December, DeLauro took direct aim at Musk, <a href="https://www.benzinga.com/news/24/12/42639184/elon-musk-accused-of-bullying-republicans-to-scrap-us-china-investment-safeguards-to-protect-teslas">accusing him of pressuring</a> Republicans to remove key restrictions on U.S. investments in China—restrictions meant to protect national security and supply chains. She pointed to Tesla's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) deep ties to China, particularly its Shanghai gigafactory, which produces around half of the company's EVs.&nbsp;</p>
<p>She argued that Musk's lobbying efforts undermine bipartisan efforts to prevent U.S. funds from flowing into strategic Chinese industries like artificial intelligence. Musk fired back on X, <a href="https://x.com/elonmusk/status/1870233561753633123">calling</a> for "this awful creature's" removal from Congress.</p>
<p><strong><em>See Also: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"><strong><em> </em></strong><strong><em>Tax deferring is their number one strategy</em></strong></a>.</em></strong></p>
<h2 class="wp-block-heading">A "Government of Billionaires"?</h2>
<p>DeLauro has painted a grim picture of what she sees as the Republican Party's endgame: slashing funding for critical services while funneling benefits to billionaires. She has warned that Trump and his allies are prepared to target Medicaid, cancer research, and other key programs next.</p>
<p>"What we cannot allow," she said, "is a government of billionaires, by billionaires, and for billionaires, to seize total control of our country."</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>


TSLA

'No, We Are Not Taking Over Gaza,' Says Influential Congresswoman—Warns Trump's Real Goal Is Helping Billionaires Gut Programs For Americans

<p>In the preceding three months, 5 analysts have released ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Bruker, presenting an average target of $68.6, a high estimate of $80.00, and a low estimate of $60.00. Experiencing a 11.2% decline, the current average is now lower than the previous average price target of $77.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739221242_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Bruker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bruker analyst ratings.</strong></a></p>
<h2>Get to Know Bruker Better</h2>
<p>Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.</p>
<h3>Financial Milestones: Bruker's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Bruker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.37%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Bruker's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.73%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bruker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.27%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Bruker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.68%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.34</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BRKR

Bruker Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>In the last three months, 4 analysts have published ratings on Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.25, along with a high estimate of $20.00 and a low estimate of $17.00. This current average has decreased by 14.12% from the previous average price target of $21.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739221234_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Utz Brands. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Baumgartner</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Utz Brands. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Utz Brands compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Utz Brands's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Utz Brands's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UTZ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Utz Brands analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Utz Brands: A Closer Look</h2>
<p>Utz Brands Inc is a snack food manufacturing company. It manufactures a diverse portfolio of salty snacks under popular brands including Utz, Zapp's, Golden Flake, Boulder Canyon, Hawaiian, TORTIYAHS!, among others. The company's products include potato chips, tortilla chips, pretzels, cheese snacks, pork skins, veggie snacks, pub/party mixes, and other snacks.. Its products are distributed nationally and internationally through grocery, mass merchant, club, convenience, drug, and other channels. It operates in the given segment: the manufacturing, distribution, marketing and sale of snack food products.</p>
<h3>Financial Insights: Utz Brands</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Utz Brands's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-1.7%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Utz Brands's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-0.6%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Utz Brands's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.32%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Utz Brands's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.08%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.26</strong>, caution is advised due to increased financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Utz Brands: Insights From 4 Analyst Reviews

FLNC

Trading Halt: Halted at 4:00:10 p.m. ET - Trading Halt: Halt News Pending

<p>Ratings for Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $123.44, a high estimate of $140.00, and a low estimate of $112.00. This current average represents a 1.59% decrease from the previous average price target of $125.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739221223_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$113.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$112.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$119.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$118.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$128.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zimmer Biomet Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Zimmer Biomet Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Zimmer Biomet Holdings analyst ratings.</strong></a></p>
<h2>Discovering Zimmer Biomet Holdings: A Closer Look</h2>
<p>Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.</p>
<h3>Zimmer Biomet Holdings's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Zimmer Biomet Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.03%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Zimmer Biomet Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>13.66%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.98%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.15%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Zimmer Biomet Holdings's debt-to-equity ratio is below the industry average at <strong>0.52</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Zimmer Biomet Holdings Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

<p>Across the recent three months, 11 analysts have shared their insights on NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated NetApp and provided 12-month price targets. The average target is $138.27, accompanied by a high estimate of $160.00 and a low estimate of $120.00. This upward trend is apparent, with the current average reflecting a 5.87% increase from the previous average price target of $130.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739221213_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of NetApp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Karl Ackerman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$132.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$121.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NetApp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NetApp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of NetApp's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of NetApp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTAP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on NetApp analyst ratings.</strong></a></p>
<h2>About NetApp</h2>
<p>NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services.</p>
<h3>NetApp's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining NetApp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.15%</strong> as of 31 October, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> NetApp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>18.03%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NetApp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>32.84%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> NetApp's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.27%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> NetApp's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.52</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTAP

Demystifying NetApp: Insights From 11 Analyst Reviews

Biotech

General

BURU

Nuburu Will Be Issued U.S. Patent Number 12,220,764 Tomorrow Titled "Visible Laser Welding of Electronic Packaging, Automotive Electrics, Battery and Other Components".

WIIM

UBER

Uber shares are trading higher on continued strength after Bill Ackman last week announced a position in the stock.

<p><a href="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/" title="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/">https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/</a></p>


Legal

AKAN

CRON

GRWG

IMCC

LFLY

MAPS

MSOS

SNDL

TLRY

"DEA Official Says Marijuana Rescheduling Is 'Delayed, But Certainly Not Dead'" - The Marijuana Herald

ACHV

Achieve Life Sciences shares are trading higher after the company announced the data safety monitoring committee did not identify any adverse events in the ORCA-OL clinical trial.

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on RegenXBio (RGNX – Research Report), with a pr...

Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)

REGENXBIO partners with Nippon Shinyaku for MPS therapies

Stifel Nicolaus analyst Annabel Samimy has reiterated their bullish stance on RGNX stock, giving a Buy rating today. Annabel Samimy has given her B...

Strategic Partnerships and Promising Pipeline Drive Buy Rating for RegenXBio

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research Report)...

Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Illumina (ILMN) and RegenXBio (RGNX)

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00. Yi Chen'...

RegenXBio: Strategic Partnerships and Promising Pipeline Drive Buy Rating

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

RBC Capital analyst Luca Issi maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $30.00. The company's s...

RegenXBio (RGNX) Gets a Buy from RBC Capital

ABBV

ANIX

ERNA

EVAX

GBIO

ILMN

KROS

LEXX

NAMS

OSTX

REGN

RGNX

SNGX

SRPT

TNFA

Press Releases

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Comments

Regenxbio

空売り

Regenxbio (NASDAQ:RGNX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル